The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication
Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity have produced superior progression-free survival comp...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 2021-03, Vol.84 (3), p.587-595 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 595 |
|---|---|
| container_issue | 3 |
| container_start_page | 587 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 84 |
| creator | Durgin, Joseph S. Weiner, David M. Wysocka, Maria Rook, Alain H. |
| description | Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity have produced superior progression-free survival compared with conventional chemotherapy, reinforcing the importance of addressing the immune deficient state in the care of patients with CTCL. Recent research has better defined the pathogenesis of these immune deficits, explaining the mechanisms of disease progression and revealing potential therapeutic targets. The features of the malignant cell in mycosis fungoides and Sézary syndrome are now significantly better understood, including the T helper 2 cell phenotype, regulatory T cell cytokine production, immune checkpoint molecule expression, chemokine receptors, and interactions with the microenvironment. The updated model of CTCL immunopathogenesis provides understanding into clinical progression and therapeutic response. |
| doi_str_mv | 10.1016/j.jaad.2020.12.027 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2473403851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S019096222033187X</els_id><sourcerecordid>2473403851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-a50bcd753a8556cf2ee75fa9ad098df3d3501bd5b1a1d43715d981b6f0c154373</originalsourceid><addsrcrecordid>eNp9UcFu1DAUtBAVXQo_wAH5yCXLs72OE8QFVVCQKtHD9mw59kvXq00cbKfV_gGfXS9ZOHJ6euOZ0RsPIe8YrBmw-uN-vTfGrTnwAvA1cPWCrBi0qqpVo16SFbAWqrbm_JK8TmkPAO1GqFfkUgghOa_Vivze7pD6YZjHMJm8Cw84YvKJmtGd4bzDaKYjDT21czYjhjnRLbV4ONDDcZh2YTCf6F0RP5njIswmPmBOtA9xMUEaMeUQTfZhXCjzUB6Ls_P2D_qGXPTmkPDteV6R-29ft9ffq9ufNz-uv9xWdgOQKyOhs05JYRopa9tzRCV70xoHbeN64YQE1jnZMcNcCcukaxvW1T1YJssursiHxXeK4ddcrtKDT6cwSzLNN0psQDSSFSpfqDaGlCL2eop-MPGoGehTA3qvTw3oUwOacV0aKKL3Z_-5G9D9k_z98kL4vBCwpHz0GHWyHkeLzke0Wbvg_-f_DIoKmpI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473403851</pqid></control><display><type>article</type><title>The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Durgin, Joseph S. ; Weiner, David M. ; Wysocka, Maria ; Rook, Alain H.</creator><creatorcontrib>Durgin, Joseph S. ; Weiner, David M. ; Wysocka, Maria ; Rook, Alain H.</creatorcontrib><description>Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity have produced superior progression-free survival compared with conventional chemotherapy, reinforcing the importance of addressing the immune deficient state in the care of patients with CTCL. Recent research has better defined the pathogenesis of these immune deficits, explaining the mechanisms of disease progression and revealing potential therapeutic targets. The features of the malignant cell in mycosis fungoides and Sézary syndrome are now significantly better understood, including the T helper 2 cell phenotype, regulatory T cell cytokine production, immune checkpoint molecule expression, chemokine receptors, and interactions with the microenvironment. The updated model of CTCL immunopathogenesis provides understanding into clinical progression and therapeutic response.</description><identifier>ISSN: 0190-9622</identifier><identifier>ISSN: 1097-6787</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2020.12.027</identifier><identifier>PMID: 33352267</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antineoplastic Agents, Immunological - pharmacology ; Antineoplastic Agents, Immunological - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; CTCL ; cutaneous T cell lymphoma ; dermatologic oncology ; Disease Progression ; drug response ; Humans ; Immune Checkpoint Inhibitors - pharmacology ; Immune Checkpoint Inhibitors - therapeutic use ; immune deficiency ; Immune Reconstitution ; Immunity, Cellular - drug effects ; immunopathogenesis ; immunotherapy ; Microbiota - immunology ; mycosis fungoides ; Mycosis Fungoides - drug therapy ; Mycosis Fungoides - immunology ; Mycosis Fungoides - mortality ; Mycosis Fungoides - pathology ; Progression-Free Survival ; Sezary Syndrome - drug therapy ; Sezary Syndrome - immunology ; Sezary Syndrome - mortality ; Sezary Syndrome - pathology ; Skin - drug effects ; Skin - immunology ; Skin - microbiology ; Skin - pathology ; Skin Neoplasms - drug therapy ; Skin Neoplasms - immunology ; Skin Neoplasms - mortality ; Skin Neoplasms - pathology ; Sézary syndrome ; Th2 Cells - drug effects ; Th2 Cells - immunology ; Tumor Escape - drug effects ; Tumor Microenvironment - drug effects ; Tumor Microenvironment - immunology</subject><ispartof>Journal of the American Academy of Dermatology, 2021-03, Vol.84 (3), p.587-595</ispartof><rights>2020 American Academy of Dermatology, Inc.</rights><rights>Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-a50bcd753a8556cf2ee75fa9ad098df3d3501bd5b1a1d43715d981b6f0c154373</citedby><cites>FETCH-LOGICAL-c400t-a50bcd753a8556cf2ee75fa9ad098df3d3501bd5b1a1d43715d981b6f0c154373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaad.2020.12.027$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33352267$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Durgin, Joseph S.</creatorcontrib><creatorcontrib>Weiner, David M.</creatorcontrib><creatorcontrib>Wysocka, Maria</creatorcontrib><creatorcontrib>Rook, Alain H.</creatorcontrib><title>The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity have produced superior progression-free survival compared with conventional chemotherapy, reinforcing the importance of addressing the immune deficient state in the care of patients with CTCL. Recent research has better defined the pathogenesis of these immune deficits, explaining the mechanisms of disease progression and revealing potential therapeutic targets. The features of the malignant cell in mycosis fungoides and Sézary syndrome are now significantly better understood, including the T helper 2 cell phenotype, regulatory T cell cytokine production, immune checkpoint molecule expression, chemokine receptors, and interactions with the microenvironment. The updated model of CTCL immunopathogenesis provides understanding into clinical progression and therapeutic response.</description><subject>Antineoplastic Agents, Immunological - pharmacology</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>CTCL</subject><subject>cutaneous T cell lymphoma</subject><subject>dermatologic oncology</subject><subject>Disease Progression</subject><subject>drug response</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - pharmacology</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>immune deficiency</subject><subject>Immune Reconstitution</subject><subject>Immunity, Cellular - drug effects</subject><subject>immunopathogenesis</subject><subject>immunotherapy</subject><subject>Microbiota - immunology</subject><subject>mycosis fungoides</subject><subject>Mycosis Fungoides - drug therapy</subject><subject>Mycosis Fungoides - immunology</subject><subject>Mycosis Fungoides - mortality</subject><subject>Mycosis Fungoides - pathology</subject><subject>Progression-Free Survival</subject><subject>Sezary Syndrome - drug therapy</subject><subject>Sezary Syndrome - immunology</subject><subject>Sezary Syndrome - mortality</subject><subject>Sezary Syndrome - pathology</subject><subject>Skin - drug effects</subject><subject>Skin - immunology</subject><subject>Skin - microbiology</subject><subject>Skin - pathology</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - immunology</subject><subject>Skin Neoplasms - mortality</subject><subject>Skin Neoplasms - pathology</subject><subject>Sézary syndrome</subject><subject>Th2 Cells - drug effects</subject><subject>Th2 Cells - immunology</subject><subject>Tumor Escape - drug effects</subject><subject>Tumor Microenvironment - drug effects</subject><subject>Tumor Microenvironment - immunology</subject><issn>0190-9622</issn><issn>1097-6787</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UcFu1DAUtBAVXQo_wAH5yCXLs72OE8QFVVCQKtHD9mw59kvXq00cbKfV_gGfXS9ZOHJ6euOZ0RsPIe8YrBmw-uN-vTfGrTnwAvA1cPWCrBi0qqpVo16SFbAWqrbm_JK8TmkPAO1GqFfkUgghOa_Vivze7pD6YZjHMJm8Cw84YvKJmtGd4bzDaKYjDT21czYjhjnRLbV4ONDDcZh2YTCf6F0RP5njIswmPmBOtA9xMUEaMeUQTfZhXCjzUB6Ls_P2D_qGXPTmkPDteV6R-29ft9ffq9ufNz-uv9xWdgOQKyOhs05JYRopa9tzRCV70xoHbeN64YQE1jnZMcNcCcukaxvW1T1YJssursiHxXeK4ddcrtKDT6cwSzLNN0psQDSSFSpfqDaGlCL2eop-MPGoGehTA3qvTw3oUwOacV0aKKL3Z_-5G9D9k_z98kL4vBCwpHz0GHWyHkeLzke0Wbvg_-f_DIoKmpI</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Durgin, Joseph S.</creator><creator>Weiner, David M.</creator><creator>Wysocka, Maria</creator><creator>Rook, Alain H.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202103</creationdate><title>The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication</title><author>Durgin, Joseph S. ; Weiner, David M. ; Wysocka, Maria ; Rook, Alain H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-a50bcd753a8556cf2ee75fa9ad098df3d3501bd5b1a1d43715d981b6f0c154373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antineoplastic Agents, Immunological - pharmacology</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>CTCL</topic><topic>cutaneous T cell lymphoma</topic><topic>dermatologic oncology</topic><topic>Disease Progression</topic><topic>drug response</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - pharmacology</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>immune deficiency</topic><topic>Immune Reconstitution</topic><topic>Immunity, Cellular - drug effects</topic><topic>immunopathogenesis</topic><topic>immunotherapy</topic><topic>Microbiota - immunology</topic><topic>mycosis fungoides</topic><topic>Mycosis Fungoides - drug therapy</topic><topic>Mycosis Fungoides - immunology</topic><topic>Mycosis Fungoides - mortality</topic><topic>Mycosis Fungoides - pathology</topic><topic>Progression-Free Survival</topic><topic>Sezary Syndrome - drug therapy</topic><topic>Sezary Syndrome - immunology</topic><topic>Sezary Syndrome - mortality</topic><topic>Sezary Syndrome - pathology</topic><topic>Skin - drug effects</topic><topic>Skin - immunology</topic><topic>Skin - microbiology</topic><topic>Skin - pathology</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - immunology</topic><topic>Skin Neoplasms - mortality</topic><topic>Skin Neoplasms - pathology</topic><topic>Sézary syndrome</topic><topic>Th2 Cells - drug effects</topic><topic>Th2 Cells - immunology</topic><topic>Tumor Escape - drug effects</topic><topic>Tumor Microenvironment - drug effects</topic><topic>Tumor Microenvironment - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Durgin, Joseph S.</creatorcontrib><creatorcontrib>Weiner, David M.</creatorcontrib><creatorcontrib>Wysocka, Maria</creatorcontrib><creatorcontrib>Rook, Alain H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Durgin, Joseph S.</au><au>Weiner, David M.</au><au>Wysocka, Maria</au><au>Rook, Alain H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2021-03</date><risdate>2021</risdate><volume>84</volume><issue>3</issue><spage>587</spage><epage>595</epage><pages>587-595</pages><issn>0190-9622</issn><issn>1097-6787</issn><eissn>1097-6787</eissn><abstract>Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity have produced superior progression-free survival compared with conventional chemotherapy, reinforcing the importance of addressing the immune deficient state in the care of patients with CTCL. Recent research has better defined the pathogenesis of these immune deficits, explaining the mechanisms of disease progression and revealing potential therapeutic targets. The features of the malignant cell in mycosis fungoides and Sézary syndrome are now significantly better understood, including the T helper 2 cell phenotype, regulatory T cell cytokine production, immune checkpoint molecule expression, chemokine receptors, and interactions with the microenvironment. The updated model of CTCL immunopathogenesis provides understanding into clinical progression and therapeutic response.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33352267</pmid><doi>10.1016/j.jaad.2020.12.027</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 2021-03, Vol.84 (3), p.587-595 |
| issn | 0190-9622 1097-6787 1097-6787 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2473403851 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use CTCL cutaneous T cell lymphoma dermatologic oncology Disease Progression drug response Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use immune deficiency Immune Reconstitution Immunity, Cellular - drug effects immunopathogenesis immunotherapy Microbiota - immunology mycosis fungoides Mycosis Fungoides - drug therapy Mycosis Fungoides - immunology Mycosis Fungoides - mortality Mycosis Fungoides - pathology Progression-Free Survival Sezary Syndrome - drug therapy Sezary Syndrome - immunology Sezary Syndrome - mortality Sezary Syndrome - pathology Skin - drug effects Skin - immunology Skin - microbiology Skin - pathology Skin Neoplasms - drug therapy Skin Neoplasms - immunology Skin Neoplasms - mortality Skin Neoplasms - pathology Sézary syndrome Th2 Cells - drug effects Th2 Cells - immunology Tumor Escape - drug effects Tumor Microenvironment - drug effects Tumor Microenvironment - immunology |
| title | The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T07%3A47%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20immunopathogenesis%20and%20immunotherapy%20of%20cutaneous%20T%20cell%20lymphoma:%20Pathways%20and%20targets%20for%20immune%20restoration%20and%20tumor%20eradication&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Durgin,%20Joseph%20S.&rft.date=2021-03&rft.volume=84&rft.issue=3&rft.spage=587&rft.epage=595&rft.pages=587-595&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2020.12.027&rft_dat=%3Cproquest_cross%3E2473403851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473403851&rft_id=info:pmid/33352267&rft_els_id=S019096222033187X&rfr_iscdi=true |